Literature DB >> 12591099

Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum.

Leonid Yavich1, Jouni Sirviö, Antti Haapalinna, Aarne Ylinen, Pekka T Männistö.   

Abstract

The effects of atipamezole, an alpha(2)-adrenoceptor antagonist, L-3,4-dihydroxyphenylalanine (L-DOPA) and the combination of these drugs on dopamine overflow were studied in dopaminergic presynaptic terminals of rat caudate and nucleus accumbens. Dopamine overflow evoked by 100 pulses of electrical stimulation of the medial forebrain bundle at a low (20 Hz) and high (50 Hz) frequency was measured by in vivo voltammetry. L-DOPA (15 mg/kg) increased dopamine overflow in the caudate nucleus, but this dose had no effects in the nucleus accumbens. Atipamezole (300 microg/kg) had no effects on its own on dopamine overflow, but it did increase the size of the readily releasable storage pool and the effects of L-DOPA treatment in both structures. The combination of the drugs increased dopamine overflow to a larger extent at high compared to low stimulation frequencies. We conclude that the rat caudate nucleus is more sensitive than the nucleus accumbens to the effects of L-DOPA, and the effects of L-DOPA treatment might be effectively enhanced by antagonism of alpha(2)-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12591099     DOI: 10.1016/s0014-2999(03)01324-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Serotonergic influence on the potentiation of D-amphetamine and apomorphine-induced rotational behavior by the alpha2-adrenoceptor antagonist 2-methoxy idazoxan in hemiparkinsonian rats.

Authors:  J Srinivasan; W J Schmidt
Journal:  J Neural Transm (Vienna)       Date:  2004-12-22       Impact factor: 3.575

2.  Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.

Authors:  Corinne Y Ostock; Joy Hallmark; Noel Palumbo; Nirmal Bhide; Melissa Conti; Jessica A George; Christopher Bishop
Journal:  Neuropharmacology       Date:  2015-03-25       Impact factor: 5.250

3.  Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Authors:  Amal Alachkar; Jonathan M Brotchie; Owen T Jones
Journal:  J Mol Neurosci       Date:  2011-05-12       Impact factor: 3.444

4.  Dopaminergic modulation of neurosecretory cells in the crayfish.

Authors:  Ramón Alvarez Alvarado; Mercedes Graciela Porras Villalobos; Gabina Calderón Rosete; Leonardo Rodríguez Sosa; Hugo Aréchiga
Journal:  Cell Mol Neurobiol       Date:  2005-03       Impact factor: 5.046

5.  Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.

Authors:  Christopher J Barnum; Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Stefanie Tignor; Anna Klioueva; Hannah Walters; Christopher Bishop
Journal:  Pharmacol Biochem Behav       Date:  2011-09-25       Impact factor: 3.533

Review 6.  Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist.

Authors:  Antti Pertovaara; Antti Haapalinna; Jouni Sirviö; Raimo Virtanen
Journal:  CNS Drug Rev       Date:  2005

7.  Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation.

Authors:  Mark S Kleven; Marie-Bernadette Assié; Cristina Cosi; Catherine Barret-Grévoz; Adrian Newman-Tancredi
Journal:  Psychopharmacology (Berl)       Date:  2004-09-24       Impact factor: 4.530

8.  The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?

Authors:  J Srinivasan; Werner J Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-29       Impact factor: 3.000

9.  Catecholamine synthesis and metabolism in the central nervous system of mice lacking alpha-adrenoceptor subtypes.

Authors:  M A Vieira-Coelho; M P Serrão; J Afonso; C E Pinto; E Moura
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

10.  Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain.

Authors:  David Moranta; Susana Esteban; Jesús A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-16       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.